<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01715987</url>
  </required_header>
  <id_info>
    <org_study_id>BMS AI463-254</org_study_id>
    <nct_id>NCT01715987</nct_id>
  </id_info>
  <brief_title>Tubular Function in Asian-American Patients Receiving TDF or ETV for HBV Treatment</brief_title>
  <official_title>A Prospective and Open-Label Study of the Effect on Proximal Tubular Function in Asian-American Patients Receiving Tenofovir Disoproxil Fumarate (TDF) or Entecavir (ETV) for HBV Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New Discovery LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New Discovery LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nucleotide anti-viral analogues, including adefovir and TDF, have demonstrated kidney&#xD;
      toxicity in HIV/HBV co-infected patients and HBV mono-infected European patients.&#xD;
      Investigators suspected similar kidney proximal tubular injury can also occur in HBV mono&#xD;
      infected Asian patients receiving TDF treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate the safety use of ETV and TDF after at&#xD;
      least 144 weeks of treatment in terms of the effects of renal tubular function as determined&#xD;
      by (1) 24 hours Urine phosphate (wasting is &gt;1200 mg daily); (2) 24 hours&#xD;
      β2-microglobulinuria (NL β2-microglobulin level, &lt;1 mg daily); (3) fractional excretion of&#xD;
      uric acid, and (4) fractional tubular reabsorption of phosphorus.&#xD;
&#xD;
      The secondary objectives are to evaluate:&#xD;
&#xD;
        1. To evaluate compare the anti-viral effects of both TDF and ETV as determined the&#xD;
           percentage of patient who achieve HBV DNA levels below 60 IU/mL (by quantitative HBV DNA&#xD;
           PCR test with lowest level of detection at 60 IU/mL) and ALT normalization by routine&#xD;
           biochemical test after 144 weeks of treatment.&#xD;
&#xD;
        2. Serological responses including percentage of patients with HBeAg loss or seroconversion&#xD;
           and HBsAg loss or seroconversion with TDF and ETV treatment in Asian-American adults&#xD;
           with CHB infection.&#xD;
&#xD;
        3. To evaluate the three-year (one year treatment before enrollment and two year treatment&#xD;
           after enrollment) the percentage of patient with anti-HBV drug resistance of TDF and&#xD;
           ETV, including genotypic mutations in Asian-American adults with CHB.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>renal tubular dysfunction</measure>
    <time_frame>at 144 week after treatment with antiviral</time_frame>
    <description>renal tubular dysfunction as determined by (1) 24 hours Urine phosphate (wasting is &gt;1200 mg daily); (2) 24 hours β2-microglobulinuria (NL β2-microglobulin level, &lt;1 mg daily); (3) fractional excretion of uric acid, and (4) fractional tubular reabsorption of phosphorus.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">48</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Tenofovir Disoproxil Fumarate</arm_group_label>
    <description>Patients who are taking Tenofovir Disoproxil Fumarate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Entecavir</arm_group_label>
    <description>Patients who are taking Entecavir.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Disoproxil Fumarate</intervention_name>
    <description>300mg, oral daily for two years</description>
    <arm_group_label>Tenofovir Disoproxil Fumarate</arm_group_label>
    <other_name>Viread</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>0.5mg oral daily for two years.</description>
    <arm_group_label>Entecavir</arm_group_label>
    <other_name>Baraclude</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood Urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Asian Americans with hepatitis B taking Entecavir or Tenofovir.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-70 year-old Asian-American male or female patients with HBeAg+ or HBeAg-CHB&#xD;
&#xD;
          -  On TDF or ETV mono-therapy for 12-24 months, not previously exposed to other oral HBV&#xD;
             drugs, nor received any type of interferon treatment in the past 12 months&#xD;
&#xD;
          -  Be willing to participate&#xD;
&#xD;
          -  Continuation of HBV treatment is medically indicated. That is for HBeAg-positive&#xD;
             subjects, HBeAg remain positive or HBeAg becomes negative but still has detectable DNA&#xD;
             by the PCR method; and for HBeAg-negative subjects, HBV DNA is either detectable or&#xD;
             undetectable by the PCR method&#xD;
&#xD;
          -  No clinical or virologic evidence of anti-HBV resistance to TDF treatment at the time&#xD;
             of entering tests&#xD;
&#xD;
          -  Serum creatinine &lt; 1.5 mg/L and estimated glomerular filtration rate (creatinine&#xD;
             clearance) ≥ 60 mL/min/1.73m2 by the Cockcroft-Gault equation:&#xD;
&#xD;
             (140-age in years)(body weight [kg] )/((72)(serum creatinine [mg/dl]) ) [Note:&#xD;
             multiply estimated rate 0. by 85 for women; use actual body weight]&#xD;
&#xD;
          -  Adequate hematologic function (absolute neutrophil count ≥ 1,500/mm3; hemoglobin ≥&#xD;
             10.0 g/dL)&#xD;
&#xD;
          -  To assure all the subjects will be regularly followed per study protocol and minimize&#xD;
             the drop off rate, the subjects have to have documented pre-treatment full evaluation&#xD;
             and necessary blood tests, medical adherence to HBV treatment, and regular follow-up&#xD;
             (i.e., on HBV treatment not missing HBV medication (TDF or ETV) for more than a week,&#xD;
             with medical follow-up for HBV treatment at least every 6 month and had all the&#xD;
             necessary labs performed.&#xD;
&#xD;
          -  In the absence of exclusion criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ethnicity: Non-Asian CHB patients&#xD;
&#xD;
          -  Age: &gt;70 years old&#xD;
&#xD;
          -  Body weight and height: BMI ≥ 30&#xD;
&#xD;
          -  Concomitant nephrotoxic agents - record all prescription and nonprescription items&#xD;
             including herbs and natural remedies, NSAIDs, acyclovir, statins, ACEI or ARBs,&#xD;
             Valproate&#xD;
&#xD;
          -  Any other antiretroviral meds, antibiotic exposure during study to be noted&#xD;
&#xD;
          -  History of HCV, HDV, or HIV co-infection&#xD;
&#xD;
          -  Prior history of clinical hepatic decompensation defined as direct (conjugated)&#xD;
             bilirubin ≥ 1.2 ULN; PT ≥ 1.2 ULN, platelets ≤ 50,000/mm3, or serum albumin ≤ 3.5&#xD;
             g/dL, ascites, jaundice, encephalopathy, or variceal hemorrhage&#xD;
&#xD;
          -  Serum α-fetoprotein ≥ 50 ng/mL&#xD;
&#xD;
          -  Evidence of hepatocellular carcinoma (HCC)&#xD;
&#xD;
          -  History of solid organ or bone marrow transplantation&#xD;
&#xD;
          -  History of malignancies in the past 5 years&#xD;
&#xD;
          -  Pregnant women, and women who are breast feeding or who believe they may wish to&#xD;
             become pregnant during the course of the study.&#xD;
&#xD;
          -  Males and females of reproductive potential who are not willing to use an effective&#xD;
             method of contraception during the study. For males, condoms should be used and for&#xD;
             females, a barrier contraception method should be used in combination with one other&#xD;
             form of contraception.&#xD;
&#xD;
          -  History of significant renal disease&#xD;
&#xD;
          -  History of significant bone disease&#xD;
&#xD;
          -  History of HTN or DM on medical treatment&#xD;
&#xD;
          -  Ongoing therapy with any of the following:&#xD;
&#xD;
               1. Nephrotoxic agents&#xD;
&#xD;
               2. Parenteral aminoglycoside antibiotics&#xD;
&#xD;
               3. Cidofovir&#xD;
&#xD;
               4. Cisplatin&#xD;
&#xD;
               5. Foscarnet&#xD;
&#xD;
               6. IV amphotericin B&#xD;
&#xD;
               7. IV pentamidine&#xD;
&#xD;
               8. Oral or IV ganciclovir&#xD;
&#xD;
               9. Cyclosporine&#xD;
&#xD;
              10. Tacrolimus&#xD;
&#xD;
              11. IV vancomycin&#xD;
&#xD;
              12. Chronic daily non-steroidal anti-inflammatory drug therapy&#xD;
&#xD;
              13. Competitors of renal excretion Systemic chemotherapeutic agents&#xD;
&#xD;
              14. Systemic corticosteroids&#xD;
&#xD;
              15. Interleukin-2 (IL-2) and other immunomodulating agents&#xD;
&#xD;
          -  Investigational agents (except with the expressed approval of the lead investigators)&#xD;
             Administration of any of the above medications must be discontinued at least 30 days&#xD;
             prior to the Baseline Visit and for the duration of the study period.&#xD;
&#xD;
               1. Known hypersensitivity to the study drugs, the metabolites or formulation&#xD;
                  excipients&#xD;
&#xD;
               2. Any other condition (including alcohol or substance abuse) or prior therapy that,&#xD;
                  in the opinion of the Investigators, would make the subject unsuitable for the&#xD;
                  study or unable to comply with dosing requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Calvin Q Pan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai School of Medicine, New York</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asian Pacific Liver Center at St. Vincent Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Discovery LLC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>October 23, 2012</study_first_submitted>
  <study_first_submitted_qc>October 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2012</study_first_posted>
  <last_update_submitted>September 5, 2017</last_update_submitted>
  <last_update_submitted_qc>September 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B</keyword>
  <keyword>Antiviral</keyword>
  <keyword>Tubular dysfunction</keyword>
  <keyword>Entecavir</keyword>
  <keyword>Tenofovir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

